Going it alone: possible outcomes for life sciences

The UK is aiming to leave the EU by March 2019. This means a lot of things are set to change in the next two years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.

Careers

Blank Rome adds to growing team with patent agent from MBHB

14 May 2026 The biotechnology and life sciences specialist joins from McDonnell Boehnen Hulbert & Berghoff, marking the fifth senior IP hire at the firm this year.

Americas

BMS signs $15.2bn deal with China’s top pharma company

14 May 2026 The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others.

More features

Five generations at work: How teams are bridging the gap

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

Squire Patton Boggs promotes partner to head Europe IP&T practice

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

INTA 2026: In-house tips on what to do in London

Appeals court eases Teva’s headache with reversal

Cancer drug researcher hit with suit over mutation-targeting tools

Going it alone: possible outcomes for life sciences

More on this story

Editor's picks

Editor's picks

More features